Fig. 5
From: Preparation and in vivo and ex vivo studies of sirolimus nano-in-situ gel ophthalmic formulation
Characterization of SR-SUS-ISG (A) Image of SR-SUS-ISG; (B) Particle size distribution and Zeta potential (n = 3); (C) Transmission electron microscopy image of SR-SUS-ISG (Scale bar: 1.0 μm); (D) Transmission electron microscopy image of SR-SUS-ISG mixed with artificial tears at 40:7 (Scale bar: 500 nm); (E) Changes in particle size and PDI of SR-SUS-ISG in 6 month (n = 3); (F) Changes in Zeta potential and content of SR-SUS-ISG in 6 month (n = 3); (G) in vitro release (n = 3); (H) Scleral permeation (n = 3); Data are presented as the mean ± SD, *p < 0.05, **p < 0.01